Intellia Therapeutics NTLA Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $155.46M-17.8% | $189.18M-16.6% | $226.75M-56.7% | $523.51M+324% | ||
| $294.42M-28.6% | $412.33M-39.8% | $685.48M+2.4% | $669.12M+7.0% | ||
| $9.47M+11.2% | $8.52M-76.6% | $36.46M+868% | $3.77M+85.5% | ||
| $527.71M-17.5% | $639.86M-35.9% | $998.33M-18.0% | $1.22B+58.2% | ||
| $17.67M-35.5% | $27.38M-16.4% | $32.76M+17.3% | $27.92M+33.2% | ||
| $842.13M-29.3% | $1.19B-8.5% | $1.3B-14.4% | $1.52B+17.4% | ||
| $20.25M+38.8% | $14.59M+95.8% | $7.45M+44.6% | $5.15M-46.6% | ||
| $7.29M-64.7% | $20.66M-6.7% | $22.14M-49.5% | $43.84M-31.2% | ||
| $103.88M-6.3% | $110.85M-3.8% | $115.21M-9.0% | $126.55M+0.6% | ||
| $170.73M-46.5% | $319.06M+27.2% | $250.81M-11.9% | $284.53M— | ||
| $12K+20.0% | $10K+11.1% | $9K0.0% | $9K+28.6% | ||
| -$2.59B-19.0% | -$2.18B-31.3% | -$1.66B-40.9% | -$1.18B-67.5% | ||
| $671.39M-23.0% | $871.96M-17.0% | $1.05B-15.0% | $1.24B+18.8% | ||
| $842.13M-29.3% | $1.19B-8.5% | $1.3B-14.4% | $1.52B+17.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Intellia Therapeutics cover its short-term obligations?
- Its current ratio is 6.10 — current assets exceed current liabilities.
- Where does Intellia Therapeutics's balance sheet data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.